Idioma:

Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin

Kunze, Kent L. ; Eddy, A. Craig ; Gibaldi, Milo ; Trager, William F.

Chirality (New York, N.Y.), 1991, Vol.3 (1), p.24-29 [Periódico revisado por pares]

New York: Wiley-Liss, Inc

Sem texto completo

Citações Citado por

Enviar para

Título:
Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin
Autor: Kunze, Kent L. ; Eddy, A. Craig ; Gibaldi, Milo ; Trager, William F.
Assuntos: Aryl Hydrocarbon Hydroxylases ; Biological and medical sciences ; chiral interactions ; competitive inhibitor ; Cytochrome P-450 CYP2C9 ; Cytochrome P-450 Enzyme Inhibitors ; drug metabolism ; enantiomers ; human liver ; Humans ; Immunomodulators ; Kinetics ; Medical sciences ; Microsomes, Liver - enzymology ; Mixed Function Oxygenases - antagonists & inhibitors ; Molecular Structure ; Pharmacology. Drug treatments ; R-warfarin ; racemate ; S-warfarin-7-hydroxylase ; Stereoisomerism ; warfarin ; Warfarin - chemistry ; Warfarin - metabolism ; Warfarin - pharmacology
É parte de: Chirality (New York, N.Y.), 1991, Vol.3 (1), p.24-29
Notas: ArticleID:CHIR530030106
ark:/67375/WNG-SHNN2P71-R
istex:AA294C5B4C7D0B7075A66F84D7ACD47669D41CA3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Inhibition of the metabolism of (S)‐warfarin, the more pharmacologically active enantiomer of the racemic drug, by (R)‐warfarin was investigated in microsomes obtained from three human livers. In each case the production of both (S)‐6‐ and (S)‐7‐hydroxywarfarin was found to be competitively inhibited by (R)‐warfarin. The Kis for inhibition of (S)‐6‐ and (S)‐7‐hydroxylation by (R)‐warfarin ranged from 7.0 to 8.4 μM and from 6.0 to 6.9 μM, respectively, while the Kms for the 6‐ and 7‐hydroxylation of (S)‐warfarin ranged from 3.6 to 3.8 μM and from 3.3 to 3.9 μM, respectively. In contrast, except for the 4′‐hydroxylation pathway (S)‐warfarin was found to be a weak inhibitor of the metabolism of (R)‐warfarin. Possible implications of these findings include the following: (1) the kinetic parameters defining the interactions of two enantiomers of a racemic drug with the cytochrome P‐450s or other macromolecular systems in the living organism can only be properly defined from experiments with the pure enantiomers, (2) an enantiomer of a racemic drug may contribute significantly to biological effect not by its inherent activity but by altering the pharmacokinetics of the eutomer, and (3) enantiomeric interactions are not easily detected unless directly sought and may be relatively common.
Editor: New York: Wiley-Liss, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin

Kunze, Kent L. ; Eddy, A. Craig ; Gibaldi, Milo ; Trager, William F.

New York: Wiley-Liss, Inc

Buscando em bases de dados remotas. Favor aguardar.